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Abstract
Background Gastrointestinal stromal tumors (GISTs)
express the receptor tyrosine kinase KIT. Most GISTs have
mutations in the KIT or PDGFRA gene, causing activation
of tyrosine kinase. Imatinib, a tyrosine kinase inhibitor
(TKI), is the ﬁrst-line palliative treatment for advanced
GISTs. Sunitinib was introduced for patients with muta-
tions not responsive to imatinib. The aim was to compare
the survival of patients with high-risk resected GISTs
treated with TKI prior to surgery with historical controls
and to determine if organ-preserving surgery was
facilitated.
Methods Ten high-risk GIST-patients had downsizing/
adjuvant TKI treatment: nine with imatinib and one with
sunitinib. The patients were matched with historical con-
trols (n = 89) treated with surgery alone, from our popu-
lation-based series (n = 259). Mutational analysis of KIT
and PDGFRA was performed in all cases. The progression-
free survival was calculated.
Results The primary tumors decreased in mean diameter
from 20.4 cm to 10.5 cm on downsizing imatinib. Four
patients with R0 resection and a period of adjuvant imati-
nib had no recurrences versus 67% in the historical control
group. Four patients with residual liver metastases have
stable disease on continuous imatinib treatment after sur-
gery. One patient has undergone reoperation with liver
resection. The downsizing treatment led to organ-preserv-
ing surgery in nine patients and improved preoperative
nutritional status in one patient.
Conclusions Downsizing TKI is recommended for
patients with bulky tumors with invasion of adjacent
organs. Sunitinib can be used for patients in case of
imatinib resistance (e.g., wild-type GISTs), underlining the
importance of mutational analysis for optimal surgical
planning.
Introduction
Surgery is the primary treatment for nonmetastatic gas-
trointestinal stromal tumors (GISTs) but alone is seldom
sufﬁcient for advanced GIST. Chemotherapy and radiation
therapy have no proven effect [1]. Imatinib mesylate, a
tyrosine kinase inhibitor (TKI) introduced in 2000, is cur-
rently considered the ﬁrst-line palliative therapy. Imatinib
binds competitively to the ATP-binding pocket of KIT
kinase I, which inhibits phosphorylation of tyrosine-con-
taining substrates, downstream signaling, and cell prolif-
eration [2]. The survival of patients with metastatic or
inoperable GISTs has improved markedly with imatinib
treatment [3].
Downsizing, or neoadjuvant, treatment is given to
reduce tumor volume and to eradicate potential micro-
scopic metastatic lesions prior to surgery. Such treatment in
selected patients with a malignant GIST can facilitate
complete resection or function-sparing surgical procedures
(e.g., salvage of the anal sphincter or gastroesophageal
junction in the elderly) [3]. Sunitinib, the second-line TKI,
has been used for patients with mutations not responsive to
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during imatinib treatment (secondary resistance), or with
drug intolerance [4]. Sunitinib exerts antitumor activity by
inhibiting the split kinase domain not only of KIT receptors
but also the VEGF, PDGF, and FLT3 receptors. Further-
more, sunitinib inhibits tumor growth indirectly by inhib-
iting angiogenesis [5].
In vitro experiments and data from clinical trials show
that the responsiveness to imatinib is dependent on the type
of KIT or PDGFRA mutation [6–8]. Tumors with KIT exon
11 deletion mutation are the most sensitive to imatinib [9].
KIT mutation in GISTs can be divided into two categories:
those diagnosed in primary tumors before treatment
(primary mutations) and those detected during treatment
with imatinib (secondary mutations) [10]; the latter can be
difﬁcult to treat [11].
Two small nonrandomized Phase II trials are currently
addressing the safety and efﬁcacy of neoadjuvant imatinib
for treatment of GIST (RTOG 0132 and NCT00112632).
The primary clinical endpoints are the response rate and
progression-free survival. The RTOG study evaluated
neoadjuvant imatinib treatment for 8 weeks before surgery
and 24 months thereafter as adjuvant treatment and is now
closed. The 2-year progression-free survival was 83% in a
group with primary GIST and 77% in a group with
recurrent or metastatic GIST [12]. The German/Austrian-
NCT study is still open for recruitment (40 patients
planned).
The purpose of this study was twofold: (1) compare the
survival of patients with high-risk resected GISTs treated
with downsizing TKI versus that of historical controls from
our population-based series and (2) determine if organ-
preserving surgery was facilitated by this treatment.
Patients and methods
Treatment group
Downsizing treatment with imatinib (400 mg/day) was
given until tumor response, as judged by computed
tomography (CT) would facilitate for a lesser, or more
functional, operation. The downsizing study group con-
sisted of 10 consecutive patients (2 women, 8 men;
mean ± SD age at surgery 63 ± 8 years, range 55–
75 years) with high-risk GIST (size [5 cm and mitotic
count[5; size[10 cm and any mitotic count; or any size
and mitotic rate [10) [13]. Seven patients had liver
metastases. The mean ± SD size of the primary tumors
was 20.4 ± 8.6 cm (range 10–35 cm). One patient who
was not responsive to imatinib during 3 months (progres-
sive disease) was switched to sunitinib at a continuous dose
of 37.5 mg/day for 9 months (Table 1).
In all patients ﬁne- or core-needle biopsies were per-
formed for diagnosis as well as mutational analysis and
determination of proliferative activity (Ki-67). The same
analyses were performed on the resected tumor specimens.
After surgery the patients were continued on adjuvant
TKI. The patients with metastatic disease received pallia-
tive treatment with TKI. Patients in the downsizing group
were diagnosed and treated between 2002 and 2008. The
study was approved by the Ethical Trial Committee at the
University of Gothenburg.
Control group
The historical controls comprised 89 individuals (44
women, 45 men) who had high-risk GIST and had been
subjected to R0/R2 resection [14] diagnosed during 1983–
2000 (i.e., from a period when surgery was the only
treatment and TKI had not yet been introduced); 33% were
metastatic at presentation. The controls were matched with
the patients according to sex, age, tumor size and site, and
maximum percent Ki-67 (max%). The mean ± SD age at
diagnosis was 66.4 ± 13.1 years (range 25–92 years). The
mean ± SD tumor size was 14.4 ± 8.0 cm (range 5–
35 cm), and the mean ± SD Ki-67 max% was 15.0% ±
14.4% (range 0.5–50.0%) (Table 2). The historical control
group and the treatment group were considered comparable
as no statistically signiﬁcant differences were detected in
sex, age, tumor size and site, or Ki-67 max%.
Mutational analysis
Mutational analysis of KIT exons 9, 11, 13, and 17 and
PDGFRA exons 12 and 18 were performed with denatu-
rating high performance liquid chromatography (dHPLC)
and bidirectional direct sequencing in all cases [15].
Statistics
Time to progression-free survival was measured from the
date of registration. Continuous data from the two groups
were compared using the nonparametric Mann–Whitney
test. Categoric data from the groups were compared using
Fisher’s exact test. Progression-free survival was recorded
from the time of the initial diagnosis to the time of ﬁrst
recurrence, progression of residual tumor, or tumor-related
death. Progression-free survival was calculated using the
Kaplan–Meier method. Failure was deﬁned as local or
distant recurrence or progression, or death due to any
cause. Differences in progression-free survival between the
downsizing group and historical control groups were
compared by the log-rank test. All statistical tests were
two-sided. A value of p\0.050 was considered statisti-
cally signiﬁcant.
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123Results
Downsizing/adjuvant treatment with TKI
Ten patients were treated with downsizing TKI (Table 1,
Fig. 1). The total mean follow-up after surgery of this
series was 49.0 ± 27.1 months (range 25–90 months). The
mean duration of downsizing TKI treatment was
4.9 ± 3.2 months (range 1–11 months) prior to surgery
followed by adjuvant imatinib at a dose of 400 mg/day for
a mean period of 17.8 ± 10.6 months (range 6–29 months)
in four patients after R0 resection; six patients with R2
resection received continuous TKI treatment after surgery.
Downsizing treatment with TKI led to a mean reduction of
the primary tumor of 48.5%.
The patient (no. 10) with tumor progression on imatinib
(3 months) was switched to sunitinib for 9 months, and the
21 cm tumor was reduced to 14 cm in diameter prior to R0
resection of the primary. The histopathologic examination
after sunitinib treatment showed that the tumor was com-
posed mainly of collagen ﬁbrous tissue with a few tumor
cells; and it was positive for KIT, DOG1, and CD34
(Fig. 2).
Mutational status
Eight of the ten patients had KIT exon 11 mutations. In one
(patient 1) no DNA could be retrieved after downsizing
treatment with imatinib because there was no residual
viable tumor tissue, and patient 10 had a wild-type (wt)
tumor (Table 1). In six patients, preoperative ﬁne- or core-
needle biopsies showed a mean Ki-67 max% of
8.8% ± 2.0%, range 5–10%); after treatment, the surgical
specimens showed a Ki-67 max% of B 1% (n = 2), 5%
Fig. 1 Progression-free survival in high risk gastrointestinal stromal
tumor (GIST) patients treated with downsizing tyrosine kinase
inhibitor (TKI) until function-sparing surgery was expected (mean
duration 4.9 months) prior to R0 resection of the primary followed by
adjuvant TKI, compared with historical controls treated with surgery
only (**p\0.01). Start date for survival was the date of diagnosis
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123(n = 1) and\1% (n = 3). In the other four cases preop-
erative ﬁne-needle biopsies did not allow estimation of
Ki-67 max%.
Clinical beneﬁt of downsizing with TKI: possibility
of organ salvage
Using the downsizing strategy, eight patients treated with
imatinib were able to avoid major surgical procedures: four
gastrectomies (one requiring diaphragm resection), two
hemihepatectomies, one Whipple procedure, and one rectal
amputation. The procedures performed were limited to
gastric resection, wedge resection of the liver, and salvage
of the pancreas and rectum, respectively. Patient 1 had a
10 kg weight loss due to a relative large esophageal GIST
but resumed normal nutritional status and increased her
exercise capacity by 45% during 11 months of preoperative
imatinib treatment. Thereafter, she underwent uneventful
Fig. 2 Computed tomography scan before and after 9 months of
downsizing sunitinib. The 21 cm tumor (a) was reduced to 14 cm (b)
in diameter prior to resection. c–f Histopathology of this tumor after
sunitinib treatment. The tumor was composed mainly of collagen
ﬁbrous tissue with scattered tumor cells (c) and was positive for KIT
(d), DOG1 (e), and CD34 (f). A major vessel is seen in the upper right
corner (*)
2094 World J Surg (2010) 34:2090–2097
123thoracoabdominal esophageal resection despite her high
age.
The patient treated with sunitinib (owing to imatinib
resistance) had a large gastric tumor involving the left liver
lobe and pancreatic head. R0 resection of the primary
lesion could be performed without hemihepatectomy or
Whipple operation after a long down-staging period
(Table 1).
Historical controls
The 89 historical controls, matched to high-risk GIST
patients, were subjected to R0/R2 resection and had a mean
follow-up of 39.2 ± 4.9 months (range 2–233 months). In
all, 56 of these patients had tumors with KIT exon 11
mutations (41 deletions, 9 missense mutations, 6 duplica-
tions); two tumors had duplication mutations in KIT exon
9, and one tumor had a missense mutation in PDGFRA
exon 12. A total of 30 patients had wild-type tumors (i.e.,
no mutations in KIT or PDGFRA) (Table 2).
The estimated progression-free survivals for the patients
in the downsizing group and the historical control group
are presented in Fig. 1. Four patients with R0 resection and
a period of adjuvant imatinib had no recurrences versus
67% in the historical control group. Four patients with
residual liver metastases have stable disease on continuous
imatinib treatment after surgery, and one patient has
undergone liver resection due to progressive disease after
90 months. In our population-based series [14], most
recurrences of high risk GIST were seen within 2 years.
Discussion
In this study, tumor reduction of high risk GISTs by
downsizing with TKI was examined. The historical group
had no TKI treatment, but the study group received TKI
both before and after surgery. Therefore, the improved
survival in the study group must be regarded as a result of
combined neoadjuvant and adjuvant TKI. The mean
duration of imatinib treatment prior to surgery was
5 months, and the mean tumor reduction was about 50%
during this period.
The duration of adjuvant TKI varied between 6 and
29 months (planned 24 months). The shorter treatment
periods were due to adverse effects of imatinib. Patients
with residual liver metastasis had continuous treatment
with imatinib.
Subsequent surgery was facilitated, and R0 resection of
the primary was easily performed in all cases; in two
patients with liver metastases, wedge resection replaced
hemihepatectomy. Of the other ﬁve patients with residual
liver metastases, one was not offered liver surgery owing to
age and bilobar lesions (patient 9), and two had multiple
bilobar lesions (patients 5, 8); liver surgery was recom-
mended for the other two with unilobar lesions (patients 6,
7), but both refused because of their good response to
imatinib. One patient (no. 8) underwent liver resection after
90 months due to progression of one metastasis and cur-
rently has stable disease.
Downsizing treatment with TKI indicated that 3 to
12 months was a sufﬁcient period to make a large primary
tumor more easily resectable; only one patient (no. 3) had
shorter treatment owing to the rapid effect of the down-
sizing treatment (1 month). Resection of involved adjacent
organs or permanent intestinal stomas was avoided in this
series. The treatment should be limited to specialized
centers with access to mutational analyses of tumor biop-
sies and functional imaging with
18F-ﬂuorodeoxyglucose
positron emission tomography (
18F-FDG-PET), as only
patients with suitable KIT mutations and objective tumor
responses should be treated for longer periods with imati-
nib prior to surgery [4]. Patients with KIT exon 9 mutation,
or wt-GIST, can be treated with sunitinib, as shown in
patient 10. The core needle biopsy indicated wt compatible
with tumor progression on imatinib, which led us to change
from imatinib to sunitinib.
Major surgical procedures were avoided in nine patients.
Eight of these patients were treated with imatinib for 1 to
6.5 months, and another patient (no. 10) had primary
treatment with imatinib for 3 months and thereafter was
treated with sunitinib for 9 months. Patient 1, with a high
age and poor general condition, had remarkably improved
nutritional status after 11 months of downsizing with
imatinib and underwent uneventful esophageal resection.
Occasional reports on the value of downsizing with TKI
have appeared in the literature. Lo et al. [16] reported
salvage of the rectum in a patient with high risk GIST (KIT
exon 11 deletion, imatinib for 10 weeks; postoperative
observation for 2 years). Ludvigsen et al. [17] reported a
case similar to our patient 10 with a tumor involving the
duodenum, liver, inferior caval vein, and kidney, which
was downsized to the extent that a Whipple procedure with
en bloc resection of the kidney could be performed
(imatinib for 9 months, postoperative observation for
2 years). A case of initially, nonresectable gastric GIST
was presented by Haller et al. [18]. This patient underwent
R0 resection after downsizing (KIT exon 11 deletion,
imatinib 10 months).
Resistance due to secondary mutations can occur during
therapy with TKI, which can result in disease progression
and conferred drug resistance [19]. Secondary resistance to
imatinib was developed in 42% of the patients in a recent
study [20]. Therefore, preoperative therapy with TKI
should be given during a limited period to ensure that
complete tumor resection and potential function-sparing
World J Surg (2010) 34:2090–2097 2095
123surgery can be carried out. Surgery should be timed toward
the period of optimal tumor response for safe surgery but
before disease progression occurs [19]. Considering the
case reports available, this takes place between 4 and
12 months of imatinib treatment [4]. In our series, the
mean duration of downsizing treatment with imatinib was
4.9 months; only 3 of the 10 patients had treatment longer
than 6 months.
Histological ﬁndings after neoadjuvant treatment are
hypocellularity, myxoid degeneration with cystic change,
necrosis, and scarring [21]. Residual viable KIT-positive
tumors are common also in responsive patients but have low
mitotic activity and show cell-cycle arrest [7]. A reduction
in glycolytic metabolism can be evidenced by
18F-FDG-
PET shortly (24–48 h) after onset of treatment [4].
Downsizing treatment with sunitinib, the second-line
TKI, has not yet been evaluated in large series. Sunitinib
has been used for palliation in patients with no primary
response to imatinib, in those with progression on imatinib
treatment due to secondary mutations, or in those who are
intolerant to imatinib. Sunitinib was then most effective for
GISTs that harbor KIT exon 9 mutation or wt (without KIT/
PDGFRA mutations) GISTs [22]. Patient 10 with a wt
GIST showed progression on imatinib and was therefore
switched to sunitinib.
Ruka et al. [23] recently reported four patients with
GISTs that were initially inoperable, imatinib-resistant, or
imatinib-intolerant and therefore treated with sunitinib. In
two patients with KIT exon 9 mutation and one with wt
KIT/PDGFRA it was possible to perform R0 resection. The
fourth patient (KIT exon 9 mutation) developed a dramatic
partial response to sunitinib that required emergency
resection of the necrotic tumor mass.
Mutational analysis is thus an important tool to select
the optimal TKI for tailored downsizing in individual
patients. Patients with KIT exon 13 and 17 mutations are
few and seem to be resistant to available TKI, so no rec-
ommendations are at hand for these cases [11].
The optimal duration of the downsizing period should be
as short as possible to avoid resistance due to selection of
clones with secondary mutations (KIT exons 13 and 17)
[24]. A randomized Phase II study recently reported that
radiographic response and tumor cell apoptosis occur
within the ﬁrst week of imatinib therapy, suggesting that a
short period may be enough in some patients [25]. Duration
from 2 months to even more than 12 months has been
published (in this study 5 months) [26]. The RTOG 0132
study used 2 to 3 months of neoadjuvant TKI [12]. A
recent Phase II imatinib trial for metastatic GIST showed a
median time to response of 2.7 months, but 25% of the
patients did not reach partial response until 5.3 months
[27], which supports our ﬁndings that some patients need
more than 5 months of neoadjuvant therapy.
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